pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,285 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1177Endpoints893BioPharma Dive344BioSpace310Fierce Biotech290onclive165raps106globenewswire health73
therapy area
allOncology7622Rare Disease1876Cardiology1743Immunology1482Hematology1323Vaccines1197Pulmonology
  • Veteran researcher warns new OMB grant rule could politicize U.S. science
    David J. Skorton, president of the Association of American Medical Colleges, writes that after four decades in research he has never seen a threat to science like the new grantmaking rule being con…
    STAT · 2mo agoRegulatoryNegative↗ source
  • Hospital finance leaders call for ending billing friction that drives high costs
    At the Healthcare Financial Management Association’s annual meeting in Maryland, hospital finance executives gathered to discuss the persistent problem of affordability in health care. While the hi…
    STAT · 2mo agoNegative↗ source
← prev
page 89 of 132
next →
fda recalls70
fda medwatch60
fda press38
1189
Psychiatry & CNS866
Ophthalmology496
Pain480
Endocrinology & Metabolism474
Infectious Disease444
  • Sciwind Biosciences seeks additional partners for obesity drug ecnoglutide after deals with Pfizer and Verdiva Bio
    Sciwind Biosciences, a Chinese biotech, has licensed its GLP-1 obesity candidate ecnoglutide to two Western companies. The first agreement grants Pfizer rights to develop and commercialize the dru…
    Endpoints · 2mo agoDealPositive↗ source
  • AstronauTx appoints Michelle Mellion as new chief medical officer
    STAT+ columnist Ed Silverman reports on the latest personnel moves in the pharmaceutical sector, a regular feature that tracks hires, promotions and departures. The most recent addition is Michell…
    STAT · 2mo agoPositive↗ source
  • WuXi AppTec Files Lawsuit Against Pentagon Over Chinese Military Designation
    WuXi AppTec, a major contract manufacturing organization in China, has filed a lawsuit in U.S. federal court. The suit challenges the U.S. Department of Defense's decision to place the company on…
    Endpoints · 2mo agoRegulatoryNeutral↗ source
  • ADA apologizes after expelling five experts for distributing editorial at diabetes conference
    At the American Diabetes Association's annual meeting in New Orleans, five diabetes researchers were expelled and warned they could be arrested after distributing paper copies of an editorial. The…
    STAT · 2mo agoNegative↗ source
  • Blood Cancer United acquires remaining supply of discontinued investigational drug Luvelta
    Blood Cancer United, a nonprofit focused on blood cancers, is purchasing the remaining inventory of Luvelta, an investigational cancer drug that has been discontinued. The acquisition aims to pres…
    STAT · 2mo agoNeutral↗ source
  • Biopharma exec pay reveals quirky perks like private jets and wildfire relief grants
    A recent review of thousands of biopharma C‑suite compensation packages found that most line items blend into the massive totals, but a few stand out for their unusual nature. Among the highlighte…
    Endpoints · 2mo agoNeutral↗ source
  • RFK Jr.’s “Make America Healthy Again” pledge shows mixed progress, tracking successes and gaps
    STAT is monitoring the promises made by Robert F. Kennedy Jr. under his “Make America Healthy Again” agenda, cataloguing which goals have been met, which remain incomplete, and which have not been…
    STAT · 2mo agoNeutral↗ source
  • Chile releases new data on effectiveness of food warning labels
    Chile's health officials have released fresh data that assess how well the country's food warning label system works. The findings add to ongoing research about whether mandatory labels influence…
    STAT · 2mo agoNeutral↗ source
  • Federal probe finds private Medicare Advantage plans deny rehab care, then reverse on appeal
    A federal investigation has revealed that the nation's largest Medicare Advantage insurers routinely deny post-acute rehabilitative services to older and disabled beneficiaries. The review found t…
    STAT · 3mo agoRegulatoryNegative↗ source
  • J&J reports positive Phase 2/3 results for Imaavy in rare autoimmune anemia, paving way for label expansion
    Johnson & Johnson announced that its drug Imaavy, already approved for myasthenia gravis, produced durable hemoglobin improvements in a Phase 2/3 trial for warm autoimmune hemolytic anemia, a rare…
    BioPharma Dive · 2mo agoPositive readoutPositive↗ source
  • Takeda’s experimental TYK2 inhibitor zasocitinib outperforms Bristol Myers’ Sotyktu in psoriasis trial
    Takeda announced that its experimental TYK2 inhibitor zasocitinib showed statistical superiority over Bristol Myers Squibb’s approved psoriasis drug Sotyktu in a head‑to‑head study. The 16‑week tr…
    BioPharma Dive · 2mo agoPositive readoutPositive↗ source
  • Actuaries predict continued rise in healthcare costs for next year
    A recent survey of actuaries from 27 health plans that serve both employer groups and individual exchange markets shows early signs of where health-care spending is headed. The respondents expect…
    Endpoints · 2mo agoNegative↗ source
  • Summit Therapeutics cancels $500 million secondary share offering citing market conditions
    Summit Therapeutics announced it would pull a planned $500 million secondary share sale just one day after the announcement, saying market conditions were unfavorable. The offering had been slated…
    BioPharma Dive · 2mo agoDealNegative↗ source
  • DHL in talks with major pharma firms to manage sites amid ongoing trade disruptions
    DHL's healthcare logistics division is currently in discussions with several leading pharmaceutical manufacturers. The drugmakers are exploring options for DHL to either assume control of their ma…
    Endpoints · 2mo agoDealNeutral↗ source
  • Summit Therapeutics cancels $500 million public offering amid weak market conditions
    Summit Therapeutics announced it is no longer pursuing a $500 million public offering, citing unfavorable market conditions. The biotech sector has recently seen record‑setting initial public offe…
    Endpoints · 2mo agoDealNegative↗ source
  • Novartis' RNA drug del-brax hits primary endpoint in early-stage FSHD trial
    Novartis reported that its antisense oligonucleotide conjugate, del-brax, achieved the primary biomarker endpoint in a Phase 1/2 study of patients with facioscapulohumeral muscular dystrophy (FSHD)…
    BioPharma Dive · 2mo agoPositive readoutPositive↗ source
  • Novartis expands molecular glue program as Medicare drug spending surges and biotech firms report new data and funding
    Novartis announced it is deepening its investment in molecular glue technology, a platform that aims to target previously undruggable proteins. The move signals the company’s confidence in the appr…
    STAT · 2mo agoPositive↗ source
  • Kardigan targets $320 million IPO to fund three late-stage heart drugs
    Kardigan, a biotech focused on cardiovascular therapies, announced plans for an initial public offering that aims to raise about $320 million. The proceeds are intended to support the development…
    Endpoints · 2mo agoDealNeutral↗ source
  • Enliven Therapeutics' early-stage study shows 48% major molecular response in CML patients
    A targeted therapy from Enliven Therapeutics, ELVN-001, produced major molecular responses in 48% of participants with chronic myeloid leukemia (CML) in a 24‑week, early‑stage trial. The study eval…
    STAT · 2mo agoPositive readoutPositive↗ source
  • Synthetic lethality hype may spark new wave of biotech mergers
    The piece highlights rising enthusiasm for synthetic lethality as a cancer‑treatment strategy, especially after recent data releases. In an early‑stage trial, Tango Therapeutics reported that pati…
    STAT · 2mo agoPositive↗ source
  • Takeda’s oral psoriasis drug outperforms Bristol Myers’ Sotyktu in Phase 3 trial
    Takeda announced that its experimental oral medication for plaque psoriasis achieved superior results compared with Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 study. The trial measur…
    Endpoints · 2mo agoPositive readoutPositive↗ source
  • Long Covid research faces funding cut as NIH terminates grant, highlighting political neglect
    Steven Phillips, a science strategist at the COVID Collaborative, notes that a two‑year study of long Covid’s impact on the nervous system was halted when the NIH withdrew its RECOVER grant, labeli…
    STAT · 3mo agoNegative↗ source
  • Genentech shuts infectious disease research unit and lays off senior scientists in latest R&D cuts
    Genentech announced another round of layoffs affecting its early research and development group. The cuts included the closure of its infectious disease research unit and the departure of several…
    Endpoints · 3mo agoLayoffsNegative↗ source